Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases

ISSN: 1566-5232 (Print)
ISSN: 1875-5631 (Online)


Volume 14, 6 Issues, 2014


Download PDF Flyer




Current Gene Therapy

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 21st of 161 in Genetics & Heredity

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Ignacio Anegon
Director INSERM UMR 1064-Center for Research in Transplantation and Immunology
CHU de Nantes. 30, boulevard
Nantes
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 5.318
5 - Year: 4.322

Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases

Author(s): Juan Pablo Mackern-Oberti, Sebastian A. Riquelme, Carolina Llanos, Camila B. Schmidt, Thomas Simon, Ignacio Anegon, Evelyn Jara, Claudia A. Riedel, Susan M. Bueno and Alexis M. Kalergis

Affiliation: Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas

Abstract

One of the major goals in the research of autoimmune diseases is to develop specific therapies to regulate the expression and function of gene products that could contribute to restoring tolerance to self-constituents and replace conventional systemic immunosuppression, which associates with important undesired side effects. Although significant progress has been made on the understanding of the pathogenesis of autoimmunity, therapies for these ailments remain substantially the same. During the last decade, different strategies such as pharmacologic or gene therapy modulation of heme oxygenase-1(HO-1) and the administration of its metabolic product, carbon monoxide (CO), have been shown to display beneficial immunoregulatory and cytoprotective properties. In different experimental autoimmune conditions, such as Experimental Autoimmune Encephalomyelitis, type-1 Diabetes and Systemic Lupus Erythematosus, genetic or pharmacological modulation of HO-1, as well as delivery of CO have shown to ameliorate disease progression. Furthermore, it has been demonstrated that dendritic cell and monocyte function can be modulated by HO-1 and/or CO. In this article, recent data relative to the immunoregulatory properties of HO-1/CO will be discussed, focusing in their potential therapeutic use to treat autoimmune diseases


Purchase Online Rights and Permissions

Article Details

Volume: 14
First Page: 1
Last Page: 1
Page Count: 1
DOI: 10.2174/1566523214666140424150308
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science